announced today that the data of the novel TYK2 inhibitor ICP-488 developed by the Company for the treatment of patients with moderate-to-severe plaque psoriasis has been released at the 2025 ...

Latest data of InnoCare’s robust oncology pipelines were presented at the 2025 ASCO Annual Meeting, involving the anti-CCR8 antibody ICP-B05 (CM369), the BCL2 inhibitor mesutoclax (ICP-248 ...

BEIJING--(BUSINESS WIRE)--Data of InnoCare ... pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting. Oral Presentation: ICP-490 is a highly potent ...

Provides an overview of how PPPs, price levels and ICP data enable a wealth of socioeconomic indicators for use by policy makers, national governments and others to track development and progress.

BEIJING, March 09, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...